Suppr超能文献

肝硬化腹水的管理

Management of cirrhotic ascites.

作者信息

Pedersen Julie Steen, Bendtsen Flemming, Møller Søren

机构信息

Centre of Functional Imaging and Research, Department of Clinical Physiology and Nuclear Medicine, and Gastro Unit, Medical Division, Hvidovre Hospital, Faculty of Health Sciences, University of Copenhagen, Denmark.

Gastro Unit, Medical Division, Hvidovre Hospital, Faculty of Health Sciences, University of Copenhagen, Denmark.

出版信息

Ther Adv Chronic Dis. 2015 May;6(3):124-37. doi: 10.1177/2040622315580069.

Abstract

The most common complication to chronic liver failure is ascites. The formation of ascites in the cirrhotic patient is caused by a complex chain of pathophysiological events involving portal hypertension and progressive vascular dysfunction. Since ascites formation represents a hallmark in the natural history of chronic liver failure it predicts a poor outcome with a 50% mortality rate within 3 years. Patients with ascites are at high risk of developing complications such as spontaneous bacterial peritonitis, hyponatremia and progressive renal impairment. Adequate management of cirrhotic ascites and its complications betters quality of life and increases survival. This paper summarizes the pathophysiology behind cirrhotic ascites and the diagnostic approaches, as well as outlining the current treatment options. Despite improved medical treatment of ascites, liver transplantation remains the ultimate treatment and early referral of the patient to a highly specialized hepatology unit should always be considered.

摘要

慢性肝衰竭最常见的并发症是腹水。肝硬化患者腹水的形成是由一系列复杂的病理生理事件引起的,这些事件涉及门静脉高压和进行性血管功能障碍。由于腹水形成是慢性肝衰竭自然病程中的一个标志,它预示着预后不良,3年内死亡率达50%。腹水患者发生自发性细菌性腹膜炎、低钠血症和进行性肾功能损害等并发症的风险很高。对肝硬化腹水及其并发症进行充分管理可改善生活质量并提高生存率。本文总结了肝硬化腹水背后的病理生理学、诊断方法,并概述了当前的治疗选择。尽管腹水的药物治疗有所改善,但肝移植仍然是最终的治疗方法,应始终考虑尽早将患者转诊至高专业化的肝病科。

相似文献

1
Management of cirrhotic ascites.
Ther Adv Chronic Dis. 2015 May;6(3):124-37. doi: 10.1177/2040622315580069.
2
Review article: Management of ascites and associated complications in patients with cirrhosis.
Aliment Pharmacol Ther. 2007 Dec;26 Suppl 2:183-93. doi: 10.1111/j.1365-2036.2007.03482.x.
3
Management of ascites and hepatorenal syndrome.
Hepatol Int. 2018 Feb;12(Suppl 1):122-134. doi: 10.1007/s12072-017-9815-0. Epub 2017 Aug 23.
5
Ascites, refractory ascites and hyponatremia in cirrhosis.
Gastroenterol Rep (Oxf). 2017 May;5(2):104-112. doi: 10.1093/gastro/gox010. Epub 2017 Apr 24.
6
Treatment for cirrhotic ascites.
Hepatol Res. 2017 Feb;47(2):166-177. doi: 10.1111/hepr.12769. Epub 2016 Jul 27.
7
Nitric oxide and renal function in cirrhotic patients with ascites: from physiopathology to practice.
Eur J Gastroenterol Hepatol. 2004 Jun;16(6):567-70. doi: 10.1097/00042737-200406000-00009.
8
Optimal Management of Cirrhotic Ascites: A Review for Internal Medicine Physicians.
J Transl Int Med. 2020 Dec 31;8(4):220-236. doi: 10.2478/jtim-2020-0035. eCollection 2020 Dec.
9
Pathophysiology, complications, and treatment of ascites.
Clin Liver Dis. 1997 May;1(1):129-55. doi: 10.1016/s1089-3261(05)70261-0.

引用本文的文献

1
The Covert Side of Ascites in Cirrhosis: Cellular and Molecular Aspects.
Biomedicines. 2025 Mar 10;13(3):680. doi: 10.3390/biomedicines13030680.
2
Correlation of Serum Prolactin Levels With Chronic Liver Disease Severity in a Tertiary Care Hospital in Eastern India.
Cureus. 2025 Jan 8;17(1):e77164. doi: 10.7759/cureus.77164. eCollection 2025 Jan.
4
Drainage of ascites in cirrhosis.
World J Hepatol. 2024 Sep 27;16(9):1245-1257. doi: 10.4254/wjh.v16.i9.1245.
5
Transitioning from the Emergency Department to a General Internist Outpatient Clinic for Paracentesis: A Qualitative Inquiry.
Dig Dis Sci. 2024 Jul;69(7):2324-2332. doi: 10.1007/s10620-024-08358-0. Epub 2024 May 3.
6
Clinical study on the relationship between liver cirrhosis, ascites, and hyponatremia.
World J Gastrointest Surg. 2024 Mar 27;16(3):751-758. doi: 10.4240/wjgs.v16.i3.751.
8
Frailty in end-stage liver disease: Understanding pathophysiology, tools for assessment, and strategies for management.
World J Gastroenterol. 2023 Dec 14;29(46):6028-6048. doi: 10.3748/wjg.v29.i46.6028.
9
Prognostic value of ascites in patients with liver cirrhosis undergoing cardiac surgery.
J Cardiothorac Surg. 2023 Oct 28;18(1):302. doi: 10.1186/s13019-023-02393-0.
10
Large Volume Paracentesis in Patients with Liver Cirrhosis Temporarily Diminishes Blood Cell Count.
Iran J Med Sci. 2023 Jul;48(4):385-392. doi: 10.30476/IJMS.2022.95859.2743.

本文引用的文献

1
To block, or not to block in advanced cirrhosis and ascites: that is the question.
Gut. 2015 Jul;64(7):1015-7. doi: 10.1136/gutjnl-2014-308424. Epub 2014 Nov 14.
3
Human serum albumin, systemic inflammation, and cirrhosis.
J Hepatol. 2014 Aug;61(2):396-407. doi: 10.1016/j.jhep.2014.04.012. Epub 2014 Apr 18.
4
Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2.
Nat Med. 2014 May;20(5):518-23. doi: 10.1038/nm.3516. Epub 2014 Apr 13.
5
Pathological bacterial translocation in liver cirrhosis.
J Hepatol. 2014 Jan;60(1):197-209. doi: 10.1016/j.jhep.2013.07.044. Epub 2013 Aug 28.
6
Evolving therapies for liver fibrosis.
J Clin Invest. 2013 May;123(5):1887-901. doi: 10.1172/JCI66028. Epub 2013 May 1.
8
Terlipressin for hepatorenal syndrome.
Cochrane Database Syst Rev. 2012 Sep 12(9):CD005162. doi: 10.1002/14651858.CD005162.pub3.
9
Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia.
Aliment Pharmacol Ther. 2012 Oct;36(7):619-26. doi: 10.1111/apt.12025. Epub 2012 Aug 21.
10
First-line treatment with cephalosporins in spontaneous bacterial peritonitis provides poor antibiotic coverage.
Scand J Gastroenterol. 2012 Feb;47(2):212-6. doi: 10.3109/00365521.2011.645502. Epub 2011 Dec 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验